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EDITORIAL
Haptoglobin and hemoglobin in subarachnoid
hemorrhage
A tale of 2 globins





Although the incidence is declining, subarachnoid hemorrhage (SAH) continues to exact
a substantial toll on society, with an estimated 20,000 aneurysmal SAHs (aSAHs) a year in the
United States.1 Outcomes have improved, but the mortality remains ≈35%, and half of the
survivors cannot return to their previous level of functioning.2 The most important prognostic
factors for outcome are the neurologic condition of the patient on admission to hospital, the
patient’s age, and preexisting hypertension.3 aSAH has a unique biphasic course, with initial or
early brain injury (reflected in the neurologic condition) and a delayed phase of brain injury
called delayed cerebral ischemia (DCI). Subarachnoid blood and specifically the erythrocytes
and their main content, hemoglobin, appear to mediate DCI in humans. Extravascular free
hemoglobin and iron released from it, whether into the CSF or the brain, are highly in-
flammatory and cytotoxic oxidants.4 The body has developed ways to mitigate this, including
synthesis of haptoglobin, which binds free hemoglobin, abrogating its toxicity. Therefore,
clearing away the hemoglobin more quickly or preventing its deleterious effects by binding
hemoglobin may decrease brain injury and improve patient outcomes from SAH.
Humans have 2 haptoglobin alleles, haptoglobin 1 and 2, that differ in their scavenging ability.4
Of the 3 possible genotypes, the haptoglobin 2-2 genotype may have reduced scavenging and
has associations with more severe phenotypes of diseases such as diabetes mellitus, cardio-
vascular disease, and renal failure.4 Patients with haptoglobin 2-2 appear more likely to develop
elevated transcranial Doppler intracranial arterial flow velocities, an indicator of vasospasm of
the intracranial arteries after SAH,5 although subsequently published data conflict on the role of
haptoglobin genotype plays in SAH outcome.
In this issue of Neurology®, Gaastra et al.6 performed an important study by collecting a large
dataset that includes haptoglobin genotypes and outcome after aSAH. The fact that the authors
collected 6 unpublished datasets along with 5 published ones demonstrates important
collaborations with the authors.6 The rigorously performed individual patient–level meta-
analysis of these 939 patients, however, showed no evidence for any effect of haptoglobin
genotype on the prespecified outcomes, including functional outcome, short-term com-
plications of aSAH such as cerebral infarction, DCI, angiographic vasospasm, and trans-
cranial Doppler flow velocities.
What reasons underlie this lack of association? Haptoglobin genotype may not influence
the outcome. On the other hand, aSAH is a complex disease with many different patient-,
disease-, and treatment-related factors contributing to patient outcome, again requiring large
datasets to detect small prognostic effects. For example, treatment intensity may obviate
the effects of haptoglobin genotype. Moreover, the modified Rankin Scale or Glasgow
Outcome Scale scores dichotomized into favorable and unfavorable outcome—a rather
blunt outcome assessment—may not have adequate sensitivity to detect small changes in
patient outcome. In summary, this study demonstrates that if haptoglobin genotype does
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have an effect on outcome, the effect size would be small
and most probably not clinically relevant.
Roughly 4.5 × 1019 molecules of hemoglobin are released
from the typical aSAH volume of ≈35 mL into the ≈50-mL
subarachnoid space, with each hemolyzing erythrocyte releasing
250 million molecules.7,8 As an acute-phase reactant, the con-
centration of haptoglobin in the CSF, normally ≈0.06 mg/dL,
would increase but would likely still be overwhelmed. Little is
known about the concentrations of haptoglobin or of the dif-
ferent proteins resulting from the different genotypes in the CSF
and brain after SAH; this remains an important area for addi-
tional work.
This study clearly demonstrates the large numbers of patients
required to move the field along and highlights the need for
national and international collaborations. Finally, as the
authors mention, different studies collect different variables,
use different definitions, and follow up patients for varying
times. Common data elements are going to be key in the
efforts to study large numbers of patients with aSAH.
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